Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification

Ophthalmologica

Volumn 229, Issue 4, 2013, Pages 187-194

  Wang, Qi Wei ^a   Yao, Ke ^a   Xu, Wen ^a   Chen, Pei Qing ^a   Shentu, Xing Chao ^a   Xie, Xin ^a   Weng, Yan ^a   Zhang, Li ^a   Jin, Chong Fei ^a   Wu, Wei ^a   Zhu, Ya Nan ^a   Yu, Yin Hui ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti inflammation; Bromfenac sodium; Cataract; Cystoid macular edema

Indexed keywords

BROMFENAC; DEXAMETHASONE; EYE DROPS; FLUOROMETHOLONE; LEVOFLOXACIN; PREDNISONE; BENZOPHENONE DERIVATIVE; BROMOBENZENE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CELL DENSITY; CONTROLLED STUDY; ENDOTHELIUM CELL; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER FLARE CELL METER; LASER FLARE CELL PHOTOMETRY; LENS IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PHOTOMETRY; PHOTON COUNT VALUE; POSTOPERATIVE INFLAMMATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; RETINAL FOVEAL THICKNESS; RETINAL THICKNESS; SENILE CATARACT; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; MACULAR EDEMA; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; UVEITIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; BROMOBENZENES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUOROMETHOLONE; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS;

EID: 84878450203     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000346847     Document Type: Article

References (21)

1. Zhao JL: Prevention of blindness is still the great challenge faced by Chinese ophthalmology. Zhonghua Yan Ke Za Zhi 2009; 45: 769-771.
2. Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009; 3: 199-210.
3. Colin J: The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007; 67: 1291-1308.
4. Perry HD, Donnenfeld ED: An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006; 7: 99-107.
5. McColgin AZ, Heier JS: Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000; 11: 3-6.
6. Oka T, Shearer T, Azuma M: Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res 2004; 29: 27-34.
7. Guex-Crosier Y: Non-steroidal anti-inflammatory drugs and ocular inflammation. Klin Monbl Augenheilkd 2001; 218: 305-308.
8. Tajika T, Isowaki A, Sakaki H: Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther 2011; 27: 43-49.
9. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006; 22: 1133-1140.
10. Kim SJ, Flach AJ, Jampol LM: Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010; 55: 108-133.
11. McGhee CN, Dean S, Danesh-Meyer H: Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25: 33-55.
12. Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, Mc-Namara TR: Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin 2011; 27: 1693-1703.
13. Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR: Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology 2011; 118: 2120-2127.
14. Donnenfeld ED, Donnenfeld A: Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006; 46: 21-40.
15. Flach AJ: Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42: 1-11.
16. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L: The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophthalmol 1988; 106: 480-483.
17. Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S: Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 2009; 87: 300-305.
18. O'Brien TP: Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005; 21: 1131-1137.
19. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S: Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2034-2038.
20. Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefansson E: Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol 2006; 244: 620-626.
21. Alio JL, Sayans JA, Chipont E: Flare-cell measurement of inflammation after uneventful cataract surgery with intraocular lens implantation. J Cataract Refract Surg 1997; 23: 935-939.